within Pharmacolibrary.Drugs.M_MusculoSkeletalSystem.M01A_AntiinflammatoryAndAntirheumaticProductsNonSteroids.M01AB09_Lonazolac;
model Lonazolac 
   extends Pharmacolibrary.Drugs.ATC.M.M01AB09;

  annotation(Documentation(
    info ="<html><body><p>Lonazolac is a non-steroidal anti-inflammatory drug (NSAID) of the anthranilic acid derivative class. It was used mainly for its analgesic and anti-inflammatory effects in conditions such as rheumatoid arthritis and other musculoskeletal disorders. Lonazolac is not widely approved or marketed today in most countries; its clinical use has essentially been discontinued.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adult humans based on class characteristics due to lack of direct published data.</p><h4>References</h4><ol><li><p>Huber, R, et al., &amp; Petitet, A (1990). [Pharmacokinetics of the antirheumatic lonazolac-Ca in humans]. <i>Arzneimittel-Forschung</i> 40(8) 918–925. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2242085/&quot;>https://pubmed.ncbi.nlm.nih.gov/2242085</a></p></li><li><p>Deneke, J, et al., &amp; Pässler, HH (1998). Transsynovial kinetics of lonazolac and its hydroxy metabolite in synovitis patients. <i>International journal of clinical pharmacology and therapeutics</i> 36(8) 418–424. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9726694/&quot;>https://pubmed.ncbi.nlm.nih.gov/9726694</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Lonazolac;
